Oncology

The United States Food and Drug Administration recently approved Afinitor (everolimus) for use in combination with Aromasin (exemestane) to treat certain postmenopausal women with advanced hormone-receptor positive, HER2-negative breast cancer.

The United States Food and Drug Administration today approved Kyprolis (carfilzomib) to treat patients with multiple myeloma who have received at least 2 prior therapies, including treatment with Velcade (bortezomib) and an immunomodulatory therapy.

An analysis of the top 200 drugs by prescriptions dispensed and total sales reveals key trends in today's pharmaceutical market.

This article-written by Michael Marlan Mohundro, PharmD; and Brice Labruzzo Mohundro, PharmD-highlights the multiple available regimens for patients with relapsed or refractory myelomas as well as new treatments that are currently being investigated in clinical trials.

Specialty Pharmacy Times spoke to Milayna Subar, MD, vice president and national practice leader in oncology for the Oncology Therapeutic Resource Center (TRC) at Express Scripts, to learn more about how access to clinical practice guidelines in oncology can help shape the complex landscape of cancer treatment.

This continuing education activity addresses the factors that increase and decrease a woman's risk for breast cancer, and includes information for pharmacists to help provide evidence-based counseling on preventative measures.

The FDA approved Genentech, Inc's pertuzumab injection (Perjeta) for use in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.

Afatinib shows promise as a treatment for patients with advanced lung adenocarcinomas who tested positive for EGFR mutations.

As industry invests billions into self-administered oncolytics, specialty pharmacy steps in. This special issue focuses on the cutting-edge, real-world practices and successes of specialty pharmacy in oncology.

Taking a comprehensive look at the ever-changing and always challenging oncology scene, we present a variety of topics and voices to understand this complex world and the significant impact of specialty pharmacists.

Walgreens Specialty Pharmacy is adding 6 medications to its oral oncology cycle management program, in a significant expansion of the comprehensive treatment and support program it provides to benefit patients, physicians and payers.

Novartis and the Broad Institute have developed a cancer cell line encyclopedia that catalogues the genetic and molecular profiles of almost 1000 human cancer cell lines used in drug research and development.

Diplomat Specialty Pharmacy's president and chief executive officer shares his thoughts about the turbulent oncology arena and how specialty pharmacists can survive the storm and prosper.

A severe shortage of the key medication for childhood leukemia appears to have been averted, but the problem is likely to reemerge in the future.

A severe shortage of the key medication for childhood leukemia appears to have been averted, but the problem is likely to reemerge in the future.